Welcome to our dedicated page for SMFR news (Ticker: SMFR), a resource for investors and traders seeking the latest updates and insights on SMFR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SMFR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SMFR's position in the market.
Sema4 Holdings Corp. (Nasdaq: SMFR) reported a strong second quarter with total revenue of $46.9 million, a 56% increase year-over-year, driven by rising diagnostic test volumes. The company performed 71,702 diagnostic tests, marking an 85% growth compared to 2020. Sema4 expanded partnerships with NorthShore University, AdventHealth, and Avera Health, and aims for approximately $500 million in revenue by 2023. Despite a net loss of $45.4 million, Sema4's merger with CM Life Sciences raised $510 million, enhancing its financial position.
Avera Health has partnered with Sema4 to enhance cancer care through a new precision medicine initiative. This collaboration will leverage Sema4’s health intelligence platform, Centrellis®, to integrate clinical and genomic data, improving treatment strategies for cancer patients. Avera's existing robust precision oncology program will be advanced further with this partnership, enabling providers to utilize data-driven insights for tailored cancer treatments. The initiative aims to deliver actionable insights and accelerate access to innovative therapies for thousands of patients across Avera’s healthcare network.
Sema4 (SMFR), a health intelligence company focused on AI and machine learning, will announce its second quarter 2021 financial results on August 16, 2021, after market close. The management, including CEO Eric Schadt and CFO Isaac Ro, will host a conference call at 4:30 p.m. ET to discuss these results. Investors can access the live call by dialing specific numbers or through a webcast on the Sema4 investor relations website. Sema4 aims to revolutionize healthcare with its Centrellis health intelligence platform, emphasizing patient partnership and data sharing for better health outcomes.
Sema4 (Nasdaq: SMFR) has announced participation in two virtual investor conferences in August 2021. Eric Schadt, Ph.D., CEO, will engage in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11 at 10:00 a.m. ET. The company will also attend the Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 17. Sema4 focuses on leveraging AI and machine learning to provide data-driven insights in healthcare, aiming to enhance patient outcomes through its Centrellis™ health intelligence platform.
Sema4 Holdings Corp will debut on Nasdaq under ticker symbols SMFR and SMFRW following its merger with CM Life Sciences. This deal is set to provide approximately $500 million in cash proceeds to fuel Sema4's growth through both organic and inorganic strategies. Sema4 leverages AI and machine learning to transform healthcare using genomic and clinical data, aiming to enhance the standard of care. Key leadership will continue under CEO Eric Schadt, with the merger approved by CM Life Sciences' stockholders.
FAQ
What is the market cap of SMFR (SMFR)?
